Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. announced that CORECTIM® Ointment 0.25% (generic name: delgocitinib), a Janus kinase (JAK) inhibitor, has been listed on the Japanese National Health Insurance drug price list as of May 26, 2021 . Torii plans to launch CORECTIM® Ointment 0.25% in Japan on June 21, 2021. CORECTIM® Ointment 0.25% is a non-steroidal, JAK inhibitor that is expected to improve autoimmune and allergic diseases by inhibiting the action of JAKs, which play key roles in immune activation signalling in cells, by suppressing the overactivation of immune responses.

In the Phase 3 comparative clinical study of CORECTIM® Ointment 0.25% in pediatric patients with atopic dermatitis (aged 2 to <16) conducted in Japan, the primary endpoint of efficacy, the percentage change of the mEASI score from baseline, has met superiority to the placebo. Safety of long-term administration of CORECTIM® Ointment 0.25% was also confirmed. JT and Torii expect CORECTIM® Ointment 0.25% to be a new option for the treatment of pediatric patients with atopic dermatitis in Japan.

CORECTIM® Ointment 0.5%, the world's first topical JAK inhibitor as an indication of atopic dermatitis in adults, has beendistributed in Japan by Torii since June 2020. JT has received manufacturing and marketing approval for CORECTIM® Ointment 0.25% for an indication of pediatric atopic dermatitis as well as approval for additional pediatric dosage and administration for CORECTIM® Ointment 0.5% in Japan on March 23, 2021. Separately, the Phase 3 clinical study in infant patients with atopic dermatitis (aged 6 to <24 months) for delgocitinib is being conducted in Japan.